Allergan

CompanyIreland

Allergan develops 3 assets, the furthest approved (dexamethasone in burns). Mostly small molecule acting on NF-κB signalling, apoptosis and NR3C1; based in Ireland.

Assets
3
Furthest
Approved
Trials
16
Signals
1

Pipeline

3

  • dexamethasone

    Glucocorticoid receptor agonist with anti-inflammatory and immunosuppressive effects

    ApprovedSmall moleculeNF-κB signallingApoptosisburnsConjunctivitis, Allergic

  • memantine

    Uncompetitive NMDA receptor antagonist protecting against glutamate excitotoxicity

    ApprovedSmall moleculeGRIN2BGRIN1Alzheimer's diseasedementia

  • testosterone

    Oral testosterone replacement therapy acting as an androgen receptor agonist.

    ApprovedSmall moleculeLipid and ceramide metabolismARhormone deficiencyhypoactive sexual desire disorder

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms10
  • Trials22
  • Signals2
  • Integrity notices1
  • Similar companies6

Updated 7 Oct 2026 · 183 sources

Intelligence